Entrada Therapeutics, Inc.
HealthcareNASDAQ:TRDA · NASDAQ Global Market
+$0.15 today
Vol 0.17M · Avg 0.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.0%
avg -0.3%
ROIC
-43.7%
avg -32.9%
ROA
-38.1%
avg -24.0%
Analysis
ROA is currently the strongest return metric at -38.1% versus its period average of -24.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dipal Doshi | Chief Executive Officer & Director | $998,250.00 | — | 50 | $526,014.00 | 1.35% |
Natarajan Sethuraman | President of Research & Development | $768,000.00 | — | 64 | $216,317.00 | 0.56% |
Nathan J. Dowden | President & Chief Operating Officer | $737,182.00 | — | 55 | $49,831.00 | 0.13% |
Karla MacDonald | Chief Corporate Affairs Officer | — | — | — | — | — |
Kerry Robert | Senior Vice President of People | — | — | — | — | — |
Sandeep Basnet | Head of Information Technology | — | — | — | — | — |
Kevin Healy | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Kory James Wentworth | Chief Financial Officer & Treasurer | — | — | 47 | $119,010.00 | 0.31% |
Jared Cohen | General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
17
$1.64M
Sells
27
$6.92M
Net Sentiment
$5.27M
Net selling
Most Active
BAKER BROS. ADVISORS LP
16 transactions
1–10 of 44
Analysis
Insiders reported 17 buys worth $1.64M and 27 sells worth $6.92M over the last 12 months. That adds up to net selling of $5.27M. BAKER BROS. ADVISORS LP was the most active insider with 16 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +7.7% (7yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +7.7% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Who manages TRDA?
Entrada Therapeutics, Inc. (TRDA) lists 9 active executives. The top listed executive is Nathan J. Dowden, President & Chief Operating Officer.
Are TRDA insiders buying or selling?
Recent insider activity shows net buying of $5.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.